BY MARKETWIRE
-
Novo Nordisk launches campaign after ban on compounded semaglutide
Marketing intensified variations of semaglutide is currently prohibited in the United States.
-
Genmab drug gets support from US authorities
A consultatory panel of the United States Fda (FDA) has actually enacted support of a referral for Genmab’s Darzalex Faspro.
-
Foundation behind Eli Lilly is now the largest in the US
Although the Lilly Endowment is currently a bigger structure in the United States than Expense Gates’ structure, it is still a lengthy means from the worth of the Novo Nordis…
-
Novo Nordisk should consider finding CEO in the US, analysts say
The drugmaker’s outgoing CEO says the company is well represented with US nationals in management, for instance the current head of the company’s US organization.
-
Sanofi to invest USD 20bn in the US
The statement from the French pharmaceutical business comes simply a couple of days after United States Head of state Donald Trump authorized an exec order to make certain consider…
-
Roche reconsiders billion-dollar investments in the US: At risk by decree
The Swiss drugmaker notes threat in Trump’s exec order on medicine rate cuts and intends to reassess financial investments of about USD 50bn in the United States.
-
Sanofi to invest USD 20bn in the US
The announcement from the French pharmaceutical company comes just a few days after US President Donald Trump signed an executive order to ensure significantly lower drug prices fo…
-
HSBC loses confidence in Coloplast’s long-term targets
A frustrating 2nd quarter and a termination of the chief executive officer has HSBC guessing that Coloplast will certainly utilize its Funding Markets Day in September to establish…
-
Media Briefing: Reliant on search, haunted by AI: publishers at a crossroads
With AI-driven updates presenting continuously and web traffic patterns changing, authors are beginning to prepare for even more zero-click searches …Read More
-
Lundbeck boss sees potential to double Alzheimer’s prescriptions on Rexulti
In the long-term, chief executive officer Charl van Zyl wishes that using Rexulti to deal with frustration in Alzheimer’s individuals will certainly represent 40% of prescrip…
